Using immunohistochemistry to analyze samples from 23 glioblastoma patients, 8 diffuse astrocytoma patients, and 5 healthy individuals, it established a SIRT2 labeling index (SIRT2-LI) to measure the percentage of cells with SIRT2 localized in the nucleus [74]. This evidence concerns the gene SIRT2 and glioblastoma.